Spatiotemporal expression of endogenous opioid processing enzymes in mouse uterus at peri-implantation
- 23 August 2015
- journal article
- Published by Springer Nature in Cell and tissue research
- Vol. 363 (2) , 555-565
Abstract
Successful implantation requires intimate interactions between a competent blastocyst and a receptive uterus. We recently demonstrated that the aberrant activation of opioid signaling by exogenous ligands adversely affects preimplantation embryonic development and subsequent implantation in mice. However, the underlying machinery governing the dynamic homeostasis of the endogenous opioid system in the uterus during early pregnancy remains elusive. We now show that all three major endogenous opioid precursors are spatiotemporally expressed in the uterus during early pregnancy. Moreover, we observe the well-coordinated expression of the synthetic enzyme prohormone convertases 1/3 (PC1/3) at lower levels and of its inhibitor proprotein convertase subtilisin/kexin type 1 inhibitor (Pcsk1n) and the degrading enzyme membrane metallo-endopeptidase (MME) at higher levels in the receptive uterus. Both estrogen and progestin tend to reduce the uterine levels of opioid ligand precursors in the ovariectomized mouse model. This tight regulation of the endogenous opioid system by PC1/3, Pcsk1n and MME has been further confirmed in physiologically related pseudopregnancy and delayed implantation mouse models. The coordinated regulation of opioid precursor biosynthesis and metabolism helps to create appropriate opioid signaling ensuring uterine receptivity for implantation. Thus, endogenous uterine opioid levels are primarily determined by the coordinated expressions of PC1/3, Pcsk1n and MME under the influence of ovarian progestin and estrogen. Our findings raise an additional cautionary note regarding the effects of opioid abuse on early pregnancy events.Keywords
This publication has 42 references indexed in Scilit:
- A Positive Feedback Loop Involving Gcm1 and Fzd5 Directs Chorionic Branching Morphogenesis in the PlacentaPLOS Biology, 2013
- Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPCThe Lancet Oncology, 2012
- Maternal treatment with opioid analgesics and risk for birth defectsAmerican Journal of Obstetrics and Gynecology, 2011
- Uterine disorders and pregnancy complications: insights from mouse modelsJournal of Clinical Investigation, 2010
- Fatty acid amide hydrolase deficiency limits early pregnancy eventsJournal of Clinical Investigation, 2006
- Mouse blastocysts release a lipid which activates anandamide hydrolase in intact uterusMolecular Human Reproduction, 2004
- Functional Characterization of ProSAASJournal of Biological Chemistry, 2002
- Dysregulated Cannabinoid Signaling Disrupts Uterine Receptivity for Embryo ImplantationJournal of Biological Chemistry, 2001
- Processing of prodynorphin by the prohormone convertase PC1 results in high molecular weight intermediate formsFEBS Letters, 1994
- Relationship of maternal substance abuse to subsequent sudden infant death syndrome in offspringThe Journal of Pediatrics, 1993